The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated MSS, BRAFV600E metastatic colorectal cancer (mCRC).
 
Van Morris
Consulting or Advisory Role - Abbvie; BioNTech SE; Bristol-Myers Squibb/Celgene; Exelixis; GlaxoSmithKline; Incyte; Pfizer
Research Funding - Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst)
 
Sarah Colby
No Relationships to Disclose
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Lutris; Navire
Consulting or Advisory Role - Alentis Therapeutics; AmMax Bio; Arcus Biosciences; AstraZeneca; AVEO; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Carina Biotech; Clasp Therapeutics; Cytovation; Dewpoint Therapeutics; EMD Serono; Erasca, Inc; Flame Biosciences; Frontier Medicines; Genentech; Harbinger Oncology, Inc; Ikena Oncology; Iterion Therapeutics; Kivu Biosciences; Marengo Therapeutics; Pfizer; Regeneron; Roche; SageMedic; SERVIER; Shionogi; T-Cypher Bio; Tachyon Therapeutics; Transcode; XAIRA Therapeutics; Zentalis; Zentalis
Research Funding - Boehringer Ingelheim; EMD Serono; Genentech; Pfizer; Roche; Zentalis
 
Katherine Guthrie
No Relationships to Disclose
 
William Chapin
Consulting or Advisory Role - GlaxoSmithKline; Merus; Replimune
Research Funding - Boehringer Ingelheim (Inst); Genentech (Inst); Merck (Inst); Merus (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Colorectal Cancer Alliance; DAVA Oncology
 
Rimini Breakstone
No Relationships to Disclose
 
Zishuo Hu
No Relationships to Disclose
 
Marwan Fakih
Consulting or Advisory Role - Abbvie; Adagene; Bayer; BMS; Delcath Systems; Iterion Therapeutics; Janssen Research & Development; Merck; Microbial Machines; Mirati Therapeutics; Roche/Genentech; Summit Therapeutics; Taiho Pharmaceutical; Tempus; Totus Medicines; Xilio Therapeutics
Research Funding - Agenus (Inst); Roche/Genentech (Inst); Verastem (Inst)
 
Sepideh Gholami
Consulting or Advisory Role - Alphasights; Boston Scientific; Delcath Systems; Iota
 
Philip Gold
No Relationships to Disclose
 
E. Gabriela Chiorean
Consulting or Advisory Role - AADi; Bristol Myers Squibb; Bristol-Myers Squibb/Celgene; Fortvita Biologics; GlaxoSmithKline; Merus; Pfizer; Purple Biotech; Regeneron; Takeda; Verastem
Research Funding - Affini-T Therapeutics (Inst); BioAtla; Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Erasca, Inc (Inst); Genentech (Inst); Gilead/Forty Seven (Inst); Lonza (Inst); Revolution Medicines (Inst); Sanofi (Inst); Sapience Therapeutics (Inst)
Travel, Accommodations, Expenses - BMS; Merus; Takeda
 
Philip Philip
Honoraria - Astellas Pharma; Bayer; BioNTech SE; incyte; Ipsen; Novocure; Seagen; SERVIER; Taiho Pharmaceutical; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Incyte
Research Funding - Bayer (Inst); BioNTech SE (Inst); Genentech (Inst); halozyme (Inst); incyte (Inst); Lilly (Inst); Merck (Inst); merus (Inst); novartis (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals